PriceTargets.com logo

Atai Life Sciences - ATAI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 470.65%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.84 As of 04/25/2024 05:32 PM ET
▼ -0.03 (-1.60%)

This chart shows the closing price for ATAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atai Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATAI

Analyst Price Target is $10.50
▲ +470.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Atai Life Sciences in the last 3 months. The average price target is $10.50, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 470.65% upside from the last price of $1.84.

This chart shows the closing price for ATAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Atai Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2024Cantor FitzgeraldReiterated RatingOverweightN/A
4/3/2024Maxim GroupUpgradeHold ➝ Buy$6.00N/A
4/3/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $15.00N/A
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
1/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
3/31/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00N/A
3/7/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00N/A
3/7/2023Credit Suisse GroupLower TargetOutperform$11.00 ➝ $9.00N/A
1/19/2023HC WainwrightLower TargetBuy$50.00 ➝ $20.00N/A
1/9/2023Loop CapitalLower Target$18.00 ➝ $10.00N/A
1/9/2023CitigroupLower TargetBuy$20.00 ➝ $10.00N/A
1/6/2023EF Hutton Acquisition Co. ILower TargetBuy$23.00 ➝ $15.00N/A
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$23.00N/A
11/1/2022Loop CapitalInitiated CoverageBuy$18.00N/A
9/1/2022CitigroupLower TargetBuy$22.00 ➝ $20.00N/A
5/20/2022HC WainwrightReiterated RatingBuy$50.00N/A
5/17/2022CitigroupLower TargetBuy$26.00 ➝ $22.00N/A
4/1/2022Canaccord Genuity GroupLower Target$28.00 ➝ $27.00N/A
3/31/2022Royal Bank of CanadaLower TargetSector Perform$12.00 ➝ $9.00N/A
1/19/2022HC WainwrightReiterated RatingBuy$50.00N/A
11/30/2021Maxim GroupInitiated CoverageBuy$25.00N/A
11/22/2021HC WainwrightBoost TargetBuy$40.00 ➝ $50.00N/A
11/16/2021Credit Suisse GroupLower TargetOutperform$25.00 ➝ $24.00N/A
11/16/2021Royal Bank of CanadaLower TargetSector Perform$19.00 ➝ $17.00N/A
11/11/2021Roth CapitalInitiated CoverageBuy$32.00N/A
10/18/2021HC WainwrightInitiated CoverageBuy$40.00N/A
9/1/2021Jefferies Financial GroupInitiated CoverageBuy$27.00N/A
8/17/2021AegisBoost TargetBuy$26.00 ➝ $27.00N/A
8/17/2021ArgusBoost TargetBuy$26.00 ➝ $27.00N/A
7/14/2021Baader BankInitiated CoverageBuy$21.00N/A
7/13/2021Cantor FitzgeraldInitiated CoverageOverweight$45.00N/A
7/13/2021Berenberg BankInitiated CoverageBuy$35.00N/A
7/13/2021CitigroupInitiated CoverageBuy$26.00N/A
7/13/2021Royal Bank of CanadaInitiated CoverageSector Perform$19.00N/A
7/13/2021Credit Suisse GroupInitiated CoverageOutperform$25.00N/A
7/13/2021CowenInitiated CoverageOutperformN/A
7/8/2021AegisInitiated CoverageBuy$26.00N/A
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2024
  • 12 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 12 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Atai Life Sciences logo
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
Read More

Today's Range

Now: $1.84
Low: $1.81
High: $1.92

50 Day Range

MA: $1.98
Low: $1.63
High: $2.60

52 Week Range

Now: $1.84
Low: $1.03
High: $2.85

Volume

814,522 shs

Average Volume

1,708,098 shs

Market Capitalization

$308.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Atai Life Sciences?

The following Wall Street analysts have issued research reports on Atai Life Sciences in the last twelve months: Cantor Fitzgerald, HC Wainwright, and Maxim Group.
View the latest analyst ratings for ATAI.

What is the current price target for Atai Life Sciences?

2 Wall Street analysts have set twelve-month price targets for Atai Life Sciences in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 461.5%. HC Wainwright has the highest price target set, predicting ATAI will reach $15.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Atai Life Sciences in the next year.
View the latest price targets for ATAI.

What is the current consensus analyst rating for Atai Life Sciences?

Atai Life Sciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATAI will outperform the market and that investors should add to their positions of Atai Life Sciences.
View the latest ratings for ATAI.

What other companies compete with Atai Life Sciences?

Other companies that are similar to Atai Life Sciences include Rani Therapeutics, Atea Pharmaceuticals, Aquestive Therapeutics, UroGen Pharma and Mereo BioPharma Group. Learn More about companies similar to Atai Life Sciences.

How do I contact Atai Life Sciences' investor relations team?

Atai Life Sciences' physical mailing address is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. The company's listed phone number is 49-89-2153-9035 and its investor relations email address is [email protected]. The official website for Atai Life Sciences is www.atai.net.cn. Learn More about contacing Atai Life Sciences investor relations.